| Similar Articles |
|---|
 |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.   |
Bio-IT World
October 2005
Dennis A. Gilbert |
The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp. |
Bio-IT World
Jul/Aug 2006
Kate McDonald |
The Next Generation in Sequencing Is SOLiD Applied Biosystems has completed the acquisition of genetic analysis company Agencourt Personal Genomics for $120 million, and hopes to bring the company's novel next-generation sequencing technology to market next year. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Bio-IT World
August 13, 2002
Malorye Branca |
The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed? |
Bio-IT World
December 10, 2002 |
Craig Venter Unvarnished (part II) The former Celera CEO covers privacy, ESTs, and his new research institutes. |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Opening the Floodgates Researchers are using exome sequencing -- zeroing in on the genes that encode proteins -- to explore the biology of certain diseases. |
Salon.com
May 1, 2000
Arthur Allen |
Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Industrial Physicist
Jennifer Ouellette |
Bioinformatics moves into the mainstream An explosion of data is being tamed with new systems |
Bio-IT World
January 13, 2003
Julia Boguslavsky |
A Sequel to the Sequence The all-but-complete human genome sequence is not only an indispensable tool for biomedical research but also a major influence on the types of instrumentation researchers will invest in. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Bio-IT World
October 2006
Kevin Davies |
Cracking the Cancer Genome Regardless of which technologies win out, or which centers win the lucrative sequencing contracts, the Cancer Genome Atlas has a sublime medical and scientific importance, underscored by the latest findings from Hopkins. |
Bio-IT World
November 19, 2004
Mark D. Uehling |
Applied Bio, Ocimum Stretch Their LIMS Vendors try to make labware sing, adding ERP, multiplatform, and project-management features. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
Bio-IT World
December 15, 2003
Zachary Zimmerman |
Learning the Language of Systems Biology Geneticist par excellence David Botstein talks about his philosophy, science, his mission for integrative science, and what he deems a success for systems biology. |
Bio-IT World
July 11, 2002
Malorye Branca |
Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed. |
Bio-IT World
March 17, 2004 |
Blood, Sweat, and Tissue Genomics Collaborative and Ardais take the lead in using IT to bring human tissue banking into the era of clinical genomics. |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
Industrial Physicist
Aug/Sep 2003
Ineke Malsch |
Protein research calls for advanced instruments The science of protein interactions is becoming a major tool in biomedical and drug development research. Carrying out and advancing such studies more efficiently and effectively, however, will require new, cutting-edge instrumentation. |
| Knowledge@Wharton |
From Skin Creams to Life Insurance to Medical Care, Biosciences Are the New Frontier of Business Opportunity Research in the biological sciences holds the potential for breakthroughs that could transform the world. But scientific advances also can be baffling and more than a little intimidating, especially for business people... |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
Wired
August 2000
Jennifer Hillner |
Area 22 The inside story of the first fully sequenced chromosome. |
Bio-IT World
November 14, 2003
Kathy Ordonez |
Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines. |
Bio-IT World
November 12, 2002
Davies et al. |
John Craig Venter Unvarnished The former Celera CEO talks about that company's politics, the future of sequencing technology, and his own genome. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
The Motley Fool
August 24, 2007
Brian Orelli |
Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it. |
Bio-IT World
March 10, 2003
Salvatore Salamone |
Common Knowledge Two heads (or more) are better than one, except when they don't share information. That's where knowledge management comes in. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
Bio-IT World
November 2005 |
News Blast Applied Biosystems contributes 400,000 primers... Researchers have discovered the full genetic sequence of many different strains of the flu... Sigma-Aldrich launches Panorama Human Cancer Version 1 Protein Functional Microarray... |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint |
Bio-IT World
August 15, 2005
Kevin Davies |
TGen's Discovery Pipeline in the Desert At the Translational Genomics Research Institute, researchers have developed an industrial-style informatics strategy and discovery infrastructure that has pinpointed some 25 disease genes in the past 24 months, many of which are pending identification. |
The Motley Fool
October 23, 2006
Jack Uldrich |
Is Microsoft on Drugs? If the company uses its new BioIT Alliance not simply to push its existing software, but also to better understand what biotech customers need and want, Microsoft's new drug habit could even provide its long-suffering shareholders a little high. |
Bio-IT World
February 18, 2004 |
The Quest for Complex Genes Genetic sleuths are homing in on genes for complex diseases with the help of new, and some not so new, tools and strategies. |
Bio-IT World
December 15, 2004
Kevin Davies |
First Trilogy Machine Installed at Mount Sinai A landmark installation for U.S. Genomics' Single Molecule Analyzer. |
Salon.com
February 13, 2001
Arthur Allen |
Size doesn't matter As scientists unveil the human genome findings, it turns out we have a lot fewer genes than we'd thought, and not many more than a fruit fly... |
Wired
November 17, 2007
Thomas Goetz |
23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons. |
The Motley Fool
December 30, 2008
Brian Orelli |
A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership. |
Salon.com
February 26, 2002
Annalee Newitz |
Genome liberation The information that details who we are is too important to be privately owned... |
IEEE Spectrum
March 2013
Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
Managed Care
August 2004
Thomas Morrow |
10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans. |
BusinessWeek
December 13, 2004
John Carey |
Craig Venter: DNA's Mapmaker Who could ever have imagined that a surfer working as a night clerk at Sears, Roebuck & Co. would eventually become the driving force behind the race to read the genetic code of humanity? |
Bio-IT World
June 17, 2004
Michael A. Goldman |
A Hip Approach to Gene Hunting IntegraGen defines the genetic blueprint of complex human diseases and delivers validated disease markers and therapeutic targets for a better diagnosis and a causal treatment of common diseases, based on its unique genomic analysis expertise. |
Bio-IT World
September 9, 2002
Kevin Davies |
The Debate Over Race Relations Are self-identified labels of race useful in large-scale population genetic studies? A provocative commentary from a leading Stanford University geneticist has fuelled controversy. |
Managed Care
November 2006
Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
Bio-IT World
April 2006
Karen Hopkin |
AGBT Meeting Puts Genome Advances Front and Center If the presentations at February's Advances in Genome Biology and Technology (AGBT) are any indication, the race to generate fresh approaches to produce more sequence for less is far from over -- and looks to be heating up. |
Chemistry World
August 22, 2014
Phillip Broadwith |
Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system. |
